Questions to Ask Before Hiring an AI Development Partner for Healthcare

For: A seed-to-Series-A digital health founder who has a validated product concept — e-pharmacy, remote diagnostics, or care coordination — and is now vetting external AI development partners, having already burned time with one generalist agency that shipped a demo but couldn't navigate HIPAA, HL7, or clinical-grade data pipelines

You've already paid the tuition. The first agency built something that demoed well, then fell apart the moment a real EHR export landed in the pipeline or a pharmacist asked why the model recommended a contraindicated drug. Now you're vetting partner number two, and every deck on your screen says "healthcare AI experience." The problem is that the phrase covers everything from a meditation chatbot to a clinical decision support system that's been audited by a hospital's compliance team. Those are not the same skill.

The most dangerous vendor in your pipeline right now isn't the one who admits they've never touched HL7. It's the one who touched it exactly once — on a clean greenfield US project — and has never had to reconcile a messy regional EHR export, a state-specific drug formulary, or a model that needs to hold up under a clinician's cross-examination instead of a demo room's applause. The questions below are designed to surface that gap quickly.

Compliance and data handling

1. Walk me through the last time you handled a PHI breach scare. What was the failure mode and what changed?

Why it matters: Anyone can recite HIPAA's Security Rule. Few teams have actually had a near-miss and rebuilt their pipeline because of it. Scar tissue is the credential.

Good answer: A specific incident — a misconfigured S3 bucket, a logging system that captured PHI in plaintext, an engineer who pulled production data into a notebook. They explain what tripped the alert, the postmortem, and the controls (BAAs with sub-processors, automated PHI scanners in CI, separated environments) that exist now.

Red flag: "We've never had an incident." Either they haven't shipped at scale, or they aren't monitoring well enough to know.

2. Show me your data residency map for a multi-region deployment.

Why it matters: If you're operating in India and the US, or planning Middle East expansion, your AI inference, training data, and audit logs each have different residency rules. DISHA, HIPAA, and UAE's PDPL don't agree on much.

Good answer: A concrete diagram showing where models are hosted, where vector embeddings live, where training data is stored, and where logs go. They mention specific services (AWS HealthLake, Azure for Health, India-based VPCs) and the tradeoffs.

Red flag: "We use AWS, it's HIPAA-eligible." That's a checkbox, not an architecture.

3. What's your protocol when a model needs to be retrained on patient data?

Why it matters: Continuous learning on PHI is where most teams quietly violate their own BAAs. De-identification done badly is worse than not done at all.

Good answer: They distinguish between de-identified, limited, and full datasets. They reference specific techniques (Safe Harbor, expert determination, differential privacy where appropriate) and explain how consent is tracked at the row level.

Red flag: Hand-waving about "anonymization."

Clinical and interoperability depth

3. Have you ever ingested a real, messy HL7 v2 feed — not FHIR, not a sandbox?

Why it matters: FHIR is the future. HL7 v2 is the present, especially in mid-tier US hospitals and almost every Indian hospital chain. Pipe-delimited segments with custom Z-segments are where junior teams melt.

Good answer: They name specific integration engines they've worked with (Mirth, Rhapsody, Iguana), describe a Z-segment they had to reverse-engineer, and explain how they handled malformed messages in production.

Red flag: They pivot to FHIR immediately. FHIR is great. It is also not what your hospital partner is going to send you.

4. How do you handle drug formulary differences across regions?

Why it matters: A drug interaction model trained on RxNorm will quietly fail in India, where brand-name prescribing dominates and the same molecule has dozens of trade names. The same model will fail differently in the UAE.

Good answer: They've mapped to local formularies before. They mention sources like India's CDSCO, NHS dm+d, or local pharmacy databases, and they understand that formulary data is never clean.

Red flag: "We use OpenAI's medical knowledge." That's a hallucination engine, not a formulary.

5. Show me an AI output your clinical advisor rejected. What did you do?

Why it matters: Every healthcare AI partner needs a clinician in the loop — not as a logo on the about page, but as someone who reviews model outputs and pushes back. The interesting answer is about the pushback.

Good answer: A specific example: "Our triage model was over-recommending teleconsults for chest pain. The cardiologist on our advisory board flagged it. We added a rule-based override and retrained with weighted samples."

Red flag: "Our model has 95% accuracy." Accuracy on what test set, judged by whom?

6. What's your evaluation framework for a clinical AI feature before it goes live?

Why it matters: Standard ML metrics (precision, recall) are necessary and insufficient. Clinical features need adversarial testing — what happens with rare presentations, with non-English inputs, with patients outside the training distribution.

Good answer: They describe a tiered eval: offline metrics, clinician review of edge cases, shadow mode in production, then phased rollout with kill switches.

Red flag: "We A/B test it." Not enough when the B variant could miss a stroke.

Engineering maturity

7. How do you version models and roll back a bad deployment?

Good answer: They use a model registry (MLflow, SageMaker, Vertex), tie model versions to data snapshots, and have a documented rollback runbook. They've actually rolled back in production.

Red flag: Models are deployed as part of the application binary, with no separation between code and weights.

8. Who owns the prompts, the fine-tuned weights, and the training data when our contract ends?

Why it matters: A surprising number of vendors retain ownership of fine-tuned models or treat prompts as their proprietary IP. You're paying to be locked in.

Good answer: Clean IP transfer terms in writing. You own everything derivative of your data.

Red flag: Vague language about "jointly developed IP."

9. What's your stance on using third-party LLM APIs for PHI?

Why it matters: OpenAI, Anthropic, and Google all offer BAAs now, but the terms differ. And for many use cases, a smaller open-weight model on your own infrastructure is the right call.

Good answer: A nuanced view. They've used Azure OpenAI under a BAA, deployed Llama or Mistral variants on private infrastructure, and can articulate when each makes sense.

Red flag: Religious commitment to one provider, or worse, casual mention of sending PHI to a non-BAA endpoint "just for prototyping."

10. Show me a production system you built that's still running without you.

Why it matters: Demo-ware vendors leave behind systems that need them forever. Real engineering teams build documentation, runbooks, and handover paths.

Good answer: A reference client whose internal team now owns the system. Permission to talk to that client.

Red flag: Every past client is still on a retainer.

Operating model

11. Who specifically will be on my project? Can I interview them?

Good answer: Named senior engineers, available for a technical conversation before contracts are signed. The clinical lead is identified.

Red flag: "We assign team members based on availability." Translation: you'll get whoever isn't busy.

12. How do you handle the gap between a research-grade model and a production system a clinician trusts?

Good answer: They talk about confidence calibration, citation/grounding for generative outputs, audit logs that let a clinician see why the model said what it said, and UX patterns that surface uncertainty rather than hide it.

Red flag: They show you a chatbot.

13. What's your incident response time for a model behaving unexpectedly in production?

Good answer: Defined SLAs, on-call rotation, monitoring that catches drift and outliers automatically, and a documented process for taking a model offline.

Red flag: "Send us an email and we'll look at it."

14. Tell me about a healthcare project that didn't work. Why?

Good answer: A real story with a real lesson — bad data, mismatched expectations, regulatory shift mid-project, a clinical workflow they underestimated.

Red flag: Every project is a success story. They're either lying or new.

15. What would you refuse to build, even if I paid you?

Why it matters: A team with healthcare maturity has a list. Autonomous diagnostic claims without clinician oversight. Models that score patients in ways that could be discriminatory. Generative outputs presented as clinical advice without grounding.

Good answer: They have opinions and they share them.

Red flag: "We build whatever the client wants."

How CodeNicely can help

If your situation looks like an e-pharmacy, remote diagnostics, or care coordination product where AI has to hold up against a clinician's review and a regulator's audit, the most relevant reference point in our portfolio is HealthPotli. That engagement involved building an AI-driven drug interaction system on top of messy real-world prescription data and Indian formulary mappings — not a clean US sandbox. The work covered de-identification pipelines, the integration layer between pharmacist workflows and model outputs, and the slow, unglamorous process of getting clinical advisors to trust what the model was producing.

That's the kind of work we do in our AI Studio: production systems where the model is one component inside a regulated, clinically scrutinized workflow. If you want a personalized assessment of where your product is and what a partnership would actually look like, that's a conversation worth having directly rather than through a deck.

The takeaway

The questions above won't tell you who the best vendor is. They'll tell you who is lying, who is over-promising, and who has actually been in the room when a model failed in front of a clinician. That's usually enough. The right partner will welcome these questions — they'll have asked themselves harder versions of them already.

Frequently Asked Questions

What's the difference between a healthcare AI vendor and a generalist AI agency?

A generalist agency can ship a working model. A healthcare AI vendor knows how that model behaves when fed a malformed HL7 message, how to document its decisions for an audit, and when to refuse a feature request that would create clinical risk. The skill gap shows up in production, not in the demo.

Should I prioritize a partner with US healthcare experience or local market experience?

Both, but local market experience is harder to substitute. US-based HIPAA experience transfers reasonably well to other jurisdictions because the underlying privacy principles overlap. Drug formularies, prescription patterns, EHR vendors, and clinical workflows do not transfer. If you're shipping in India or the Middle East, a partner who has only worked with US data will rebuild a lot of assumptions on your dime.

How do I verify a vendor's clinical advisory claims?

Ask to speak with the named clinician for fifteen minutes. Real advisors will take the call. Ask them how often they review model outputs, what they've pushed back on recently, and how disagreements are resolved. A logo on a website is not an advisor.

What does a healthcare AI engagement with CodeNicely typically cost and how long does it take?

It depends entirely on scope, regulatory surface area, integrations, and the maturity of your existing data. Rather than quote a range that won't match your situation, contact CodeNicely for a personalized assessment based on your product stage and target markets.

Is it worth building AI features in-house instead of with a partner?

Eventually, yes — most digital health companies should own their AI capability over time. The question is sequencing. A partner who builds with handover in mind, documents thoroughly, and trains your team can get you to production faster and leave you with a system you can own. A partner who keeps the keys is the wrong choice regardless of how good their first build is.